Cartilage Biology and Orthopaedics Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
J Cell Mol Med. 2011 Nov;15(11):2377-88. doi: 10.1111/j.1582-4934.2010.01225.x.
Mesenchymal stem cell (MSC) therapy is a promising approach to promote tissue regeneration by either differentiating the MSCs into the desired cell type or by using their trophic functions to promote endogenous tissue repair. These strategies of regenerative medicine are limited by the availability of MSCs at the point of clinical care. Our laboratory has recently identified multipotent mesenchymal progenitor cells (MPCs) in traumatically injured muscle tissue, and the objective of this study was to compare these cells to a typical population of bone marrow derived MSCs. Our hypothesis was that the MPCs exhibit multilineage differentiation and expression of trophic properties that make functionally them equivalent to bone marrow derived MSCs for tissue regeneration therapies. Quantitative evaluation of their proliferation, metabolic activity, expression of characteristic cell-surface markers and baseline gene expression profile demonstrate substantial similarity between the two cell types. The MPCs were capable of differentiation into osteoblasts, adipocytes and chondrocytes, but they appeared to demonstrate limited lineage commitment compared to the bone marrow derived MSCs. The MPCs also exhibited trophic (i.e. immunoregulatory and pro-angiogenic) properties that were comparable to those of MSCs. These results suggest that the traumatized muscle derived MPCs may not be a direct substitute for bone marrow derived MSCs. However, because of their availability and abundance, particularly following orthopaedic injuries when traumatized muscle is available to harvest autologous cells, MPCs are a promising cell source for regenerative medicine therapies designed to take advantage of their trophic properties.
间充质干细胞（MSC）疗法是一种很有前途的方法，可以通过将 MSCs 分化为所需的细胞类型，或利用其营养功能促进内源性组织修复来促进组织再生。这些再生医学策略受到临床治疗时 MSC 可用性的限制。我们的实验室最近在创伤性损伤的肌肉组织中鉴定出多能间充质祖细胞（MPC），本研究的目的是将这些细胞与典型的骨髓来源 MSCs 进行比较。我们的假设是，MPC 表现出多能性分化和营养特性的表达，使它们在功能上等同于骨髓来源的 MSCs，可用于组织再生治疗。对其增殖、代谢活性、特征性细胞表面标志物表达和基线基因表达谱的定量评估表明，两种细胞类型之间存在显著相似性。MPC 能够分化为成骨细胞、脂肪细胞和成软骨细胞，但与骨髓来源的 MSCs 相比，它们似乎表现出有限的谱系承诺。MPC 还表现出营养（即免疫调节和促血管生成）特性，与 MSCs 相当。这些结果表明，源自创伤肌肉的 MPC 可能不是骨髓来源的 MSCs 的直接替代品。然而，由于其可用性和丰富性，特别是在骨科损伤时可收获自体细胞的创伤性肌肉，MPC 是一种有前途的再生医学治疗的细胞来源，可以利用其营养特性。
